Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25; deep and sustained benefits observed through Month 12 after a single course of therapy in Phase 2b trial ...

Seamless Therapeutics, today announced the appointment of Alvin Shih, M.D., M.B.A., as an Independent Director to its Board.